Corneal Changes in Estrogen-Dependent Breast Cancer After Hormonal Treatment
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Sohag University
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- tear break up time test and shirmer test
Study Overview
Brief Summary
Aromatase inhibitors (AI) therapy is the treatment of choice for estrogen receptor-positive breast cancer (BC). While AIs effectively suppress tumor growth, estrogen deprivation may have negative impacts on the eyes. This work evaluated the anterior segment changes in estrogen-dependent BC after hormonal treatment.
Detailed Description
Aromatase inhibitors (AI) therapy is an important treatment for estrogen receptor-positive breast cancer (BC). This work evaluated the eye anterior segment changes in estrogen-dependent BC after hormonal treatment.
This cross-sectional study was conducted on female patients aged ≥18 who received treatment for BC. Patients were evaluated by a number of tests to determine the effects on the cornea and the lacrimal system
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Females diagnosed with breast cancer
Exclusion Criteria
- •uncontrolled diabetes , auto immune diseases
Arms & Interventions
patients with breast cancer recieving hormonal treatment
evaluation of the effect of hormonal treatment on the cornea
Intervention: Hormonal treatment (Drug)
Outcomes
Primary Outcomes
tear break up time test and shirmer test
Time Frame: 6 months
these tests done before starting treatment and in follow up after recieving treatment to evaluate the lacrimal function and dry eye
Secondary Outcomes
- Corneal thickness and endothelium hexagonality(6 months)
Investigators
Haitham Thabit
Dr.
Sohag University